Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their price objective on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Stock Down 2.2 %

EVGN stock opened at $1.76 on Friday. The business has a 50 day moving average price of $2.62 and a 200 day moving average price of $4.78. Evogene has a fifty-two week low of $1.70 and a fifty-two week high of $10.40. The stock has a market cap of $9.45 million, a price-to-earnings ratio of -0.44 and a beta of 1.43.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The business had revenue of $0.91 million for the quarter. Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.